AbCellera (ABCL) announced the appointment of Sarah Noonberg as Chief Medical Officer. Noonberg brings over two decades of industry experience leading development programs from discovery through to global regulatory approvals and commercialization. Most recently, she was the Chief Medical Officer of Metagenomi (MGX).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- AbCellera doses first participants in Phase 1 trial of ABCL575
- AbCellera Biologics Earnings Call: Clinical Progress and Financial Insights
- AbCellera price target raised to $7 from $5 at BMO Capital
- AbCellera Biologics Advances Clinical Trials and Revenue Growth
- AbCellera Biologics: Promising Pipeline and Strategic Focus Justify Buy Rating